PCRX Valuation

Pacira Biosciences Inc

Add to Watchlist

Advanced Chart

21.820

-0.43(-1.933%)1D

Overview
Forecast
Valuation
Earnings

PCRX Relative Valuation

PCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PCRX is overvalued; if below, it's undervalued.

Historical Valuation

Pacira Biosciences Inc (PCRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.43 is considered Undervalued compared with the five-year average of 13.93. The fair price of Pacira Biosciences Inc (PCRX) is between 23.61 to 50.34 according to relative valuation methord. Compared to the current price of 21.82 USD , Pacira Biosciences Inc is Undervalued By 7.59%.

Relative Value

Fair Zone

23.61-50.34

Current Price：21.82

7.59%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.26

P/B

Median3y

1.86

Median5y

2.86

15.47

FCF Yield

Median3y

11.85

Median5y

8.02

Competitors Valuation Multiple

The average P/S ratio for PCRX's competitors is 3.24, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX) exhibits a P/S ratio of 1.36, which is -57.87% above the industry average. Given its robust revenue growth of 1.08%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PCRX.O

Pacira Biosciences Inc

1.36

Average P/S: 3.24

1.08%